Pacira reported $126.1M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Astellas Pharma JPY 1.1T 134.96B Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Cara Therapeutics USD 8.08M 3.18M Sep/2026
Coherus Biosciences USD 75.51M 56.82M Jun/2026
Heron Therapeutics USD 89.85M 2.3M Sep/2026
Ironwood Pharmaceuticals USD 34.73M 1.88M Sep/2026
J&J USD 55.46B 562M Sep/2026
Ligand Pharmaceuticals USD 500.57M 453.83M Sep/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Novo Nordisk DKK 239.08B 13.92B Jun/2026
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 126.1M 4.08M Sep/2026
Perrigo USD 1.02B 34.4M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Supernus Pharmaceuticals USD 285.4M 61.98M Sep/2026
Teva Pharmaceutical Industries USD 15.42B 221M Sep/2026
Xeris Pharmaceuticals USD 134.48M 55.09M Sep/2026
Zoetis USD 2.68B 621M Sep/2026